Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today shared data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) in an oral presentation by Dr. Maria Reig at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2022) in Barcelona.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2022) which will be held October 26-28, 2022 at the CCIB in Barcelona.
(Click the title for the complete article)
NMS Group S.p.A. announced appointment of Lincoln Pan to Board of Directors
Nerviano, 19, October 2022_NMS Group S.p.A., the largest oncological R&D company in Italy, announced the appointment of Mr. Lincoln Pan to its Board of Directors, effective immediately.
“We are pleased to welcome my PAG colleague Lincoln to the NMS Group Board,” said David Wong, chairman of NMS Group. “Lincoln’s deep experience in increasing the value of our global investments with strong financial oversight will be invaluable to NMS Group as we continue to grow our business.”
(Click the title for the complete article)
NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR
NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) will be reported in an oral presentation by Dr. Maria Reig at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2022) which will be held October 26-28, 2022 at the CCIB in Barcelona.
(Click the title for the complete article)
Accelera Srl Announces Change in Board Composition Effective Today
Accelera Srl, leading CRO and a member of the NMS Group today announced the change in its Board Composition, following the resignation of its board member Enrico Pesenti, effective today. Hugues Dolgos, Pharm.D., CEO of NMS Group, is appointed as Sole Director of Accelera Srl.
(Click the title for the complete article)
NerPharMa Srl Announces Change in Board Composition Effective Today
Nerviano_October_1_2022_NerPharMa Srl, leading CMO and a member of the NMS Group today announced the change in its Board Composition, following the resignation of its board member Enrico Pesenti, effective today. Hugues Dolgos, Pharm.D., CEO of NMS Group, is appointed as Sole Director of NerPharMa Srl.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck
21 September 2022 – Nerviano Medical Sciences S.r.l. (NMS) announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. Expands US Presence
Nerviano Medical Sciences S.r.l. (NMS Srl), announced today that it has expanded its presence in the US with the creation of a new US subsidiary, Nerviano Medical Sciences Inc. Nerviano Medical Sciences Inc. is incorporated in Delaware State while the company’s activities will be mostly concentrated in the Boston, Massachusetts area. The US subsidiary is part of NMS Srl and its holding NMS Group’s aggressive transformation plan to fortify further the Group’s footprint and accelerate its pace in expanding in the world’s key biotech and pharmaceutical market.
(Click the title for the complete article)
Nerviano Medical Sciences S.r.l. Announces First Patient Dosed in Phase 1 Clinical Trial of NMS-812 for The Treatment of Relapsed Refractory Multiple Myeloma (MM).
NMS-812 is a novel potent oral inhibitor of PERK (PKR-like endoplasmic reticulum kinase) that also inhibits GCN2 (General Control Nonderepressible 2). PERK and GCN2 are effectors of the Integrated Stress Response (ISR), a pro-survival pathway exploited by cancer cells to survive stress. PERK is a key effector of the unfolded protein response (UPR) and GCN2 is a sensor of amino acid deficiency. Both proteins modulate the eIF2α/ATF4 axis promoting tumor survival and drug resistance as well as, via direct and indirect mechanisms, the immune response.
(Click the title for the complete article)
NMS Group S.p.A. has approved the 2021 Financial Statements with positive outlook for 2022
Nerviano, 29 June 2022
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021.
(Click the title for the complete article)
Our Archive
Welcome and Check out our new motion picture!